rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease

Experimental Neurology

Volumn 207, Issue 2, 2007, Pages 289-301

  Manfredsson, Fredric P ^a   Burger, Corinna ^a   Sullivan, Layla F ^a   Muzyczka, Nicholas ^a   Lewin, Alfred S ^a   Mandel, Ronald J ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Basal ganglia; Dopamine; Gene transfer; Proteasomal processing

Indexed keywords

AMPHETAMINE; DOPAMINE; GREEN FLUORESCENT PROTEIN; OXIDOPAMINE; PARKIN; PARVOVIRUS VECTOR; TYROSINE 3 MONOOXYGENASE;

ADENO ASSOCIATED VIRUS; AKINESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; FORELIMB; HEMISPHERE; INNERVATION; MOTOR DYSFUNCTION; NEUROTRANSMISSION; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DOPAMINE; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; MALE; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; SUBSTANTIA NIGRA; SYMPATHOLYTICS; UBIQUITIN-PROTEIN LIGASES;

EID: 34548741834     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2007.06.019     Document Type: Article

References (51)

1. Betarbet R., Sherer T.B., and Greenamyre J.T. Ubiquitin-proteasome system and Parkinson's diseases. Exp. Neurol. 191 Suppl 1 (2005) S17-S27
2. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., Dekker M.C., Squitieri F., Ibanez P., Joosse M., van Dongen J.W., Vanacore N., van Swieten J.C., Brice A., Meco G., van Duijn C.M., Oostra B.A., and Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 (2003) 256-259
3. Bossy-Wetzel E., Schwarzenbacher R., and Lipton S.A. Molecular pathways to neurodegeneration. Nat. Med. 10 Suppl (2004) S2-S9
4. Burger C., Gorbatyuk O.S., Velardo M.J., Peden C.S., Williams P., Zolotukhin S., Reier P.J., Mandel R.J., and Muzyczka N. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Molec. Ther. 10 (2004) 302-317
5. Burger C., Nguyen F.N., Deng J., and Mandel R.J. Systemic mannitol-induced hyperosmolality amplifies rAAV2-mediated striatal transduction to a greater extent than local co-infusion. Molec. Ther. 11 (2005) 327-331
6. Conway J.E., Rhys C.M., Zolotukhin I., Zolotukhin S., Muzyczka N., Hayward G.S., and Byrne B.J. High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. Gene Ther. 6 (1999) 986-993
7. Cookson M.R. Roles of the proteasome in neurodegenerative disease: refining the hypothesis. Ann. Neurol. 56 (2004) 315-316
8. Cookson M.R. The biochemistry of Parkinson's disease. Annu. Rev. Biochem. 74 (2005) 29-52
9. Cookson M.R., Xiromerisiou G., and Singleton A. How genetics research in Parkinson's disease is enhancing understanding of the common idiopathic forms of the disease. Curr. Opin. Neurol. 18 (2005) 706-711
10. Goldberg M.S., Pisani A., Haburcak M., Vortherms T.A., Kitada T., Costa C., Tong Y., Martella G., Tscherter A., Martins A., Bernardi G., Roth B.L., Pothos E.N., Calabresi P., and Shen J. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 45 (2005) 489-496
11. Greenamyre J.T., Betarbet R., and Sherer T.B. The rotenone model of Parkinson's disease: genes, environment and mitochondria. Parkinsonism Relat. Disord. 9 Suppl 2 (2003) S59-S64
12. Gundersen H.J., Bagger P., Bendtsen T.F., Evans S.M., Korbo L., Marcussen N., Moller A., Nielsen K., Nyengaard J.R., Pakkenberg B., et al. The new stereological tools: dissector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 96 (1988) 857-881
13. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 53 Suppl 3 (2003) S26-S36 (discussion S36-28)
14. Jiang H., Jiang Q., and Feng J. Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter. J. Biol. Chem. 279 (2004) 54380-54386
15. Kirik D., Rosenblad C., and Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152 (1998) 259-277
16. Kirik D., Rosenblad C., Bjorklund A., and Mandel R.J. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J. Neurosci. 20 (2000) 4686-4700
17. Kirik D., Georgievska B., Burger C., Winkler C., Muzyczka N., Mandel R.J., and Bjorklund A. Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of l-dopa using rAAV-mediated gene transfer. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 4708-4713
18. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., and Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
19. Klein R.L., Lewis M.H., Muzyczka N., and Meyer E.M. Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer. Brain Res. 847 (1999) 314-320
20. Klein R.L., Dayton R.D., Henderson K.M., and Petrucelli L. Parkin is protective for substantia nigra dopamine neurons in a tau gene transfer neurodegeneration model. Neurosci. Lett. 401 (2006) 130-135
21. LaVoie M.J., Ostaszewski B.L., Weihofen A., Schlossmacher M.G., and Selkoe D.J. Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 11 (2005) 1214-1221
22. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M.J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P.J., Wilkinson K.D., and Polymeropoulos M.H. The ubiquitin pathway in Parkinson's disease. Nature 395 (1998) 451-452
23. Lo Bianco C., Schneider B.L., Bauer M., Sajadi A., Brice A., Iwatsubo T., and Aebischer P. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 17510-17515
24. Mandel R.J., Spratt S.K., Snyder R.O., and Leff S.E. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 14083-14088
25. Marazziti D., Golini E., Mandillo S., Magrelli A., Witke W., Matteoni R., and Tocchini-Valentini G.P. Altered dopamine signaling and MPTP resistance in mice lacking the Parkinson's disease-associated GPR37/parkin-associated endothelin-like receptor. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 10189-10194
26. Nikolaev A.Y., and Gu W. PARC: a potential target for cancer therapy. Cell Cycle 2 (2003) 169-171
27. Niwa H., Yamamura K., and Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108 (1991) 193-199
28. Olanow C.W., Perl D.P., DeMartino G.N., and McNaught K.S. Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol. 3 (2004) 496-503
29. Olsson M., Nikkhah G., Bentlage C., and Bjorklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping tests. J. Neurosci. 15 (1995) 3863-3875
30. Paterna J.C., Leng A., Weber E., Feldon J., and Bueler H. DJ-1 and Parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice. Molec. Ther. 15 (2007) 698-704
31. Perez F.A., and Palmiter R.D. Parkin-deficient mice are not a robust model of parkinsonism. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 2174-2179
32. Perez F.A., Curtis W.R., and Palmiter R.D. Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity. BMC Neurosci. 6 (2005) 71
33. Picariello L., Sala S.C., Martineti V., Gozzini A., Aragona P., Tognarini I., Paglierani M., Nesi G., Brandi M.L., and Tonelli F. A comparison of methods for the analysis of low abundance proteins in desmoid tumor cells. Anal. Biochem. 354 (2006) 205-212
34. Rosenblad C., Kirik D., Devaux B., Moffat B., Phillips H.S., and Bjorklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur. J. Neurosci. 11 (1999) 1554-1566
35. Schallert T., and Tillerson J.L. Intervention strategies for degeneration of dopamine neurons in Parkisonism: optimizing behavioral assessment of outcome. Innovative models of CNS disease: from molecule to therapy (1999), Humana Press, Clifton, NJ 131-151
36. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., and Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39 (2000) 777-787
37. Schlossmacher M.G., Frosch M.P., Gai W.P., Medina M., Sharma N., Forno L., Ochiishi T., Shimura H., Sharon R., Hattori N., Langston J.W., Mizuno Y., Hyman B.T., Selkoe D.J., and Kosik K.S. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am. J. Pathol. 160 (2002) 1655-1667
38. Shimura H., Hattori N., Kubo S., Mizuno Y., Asakawa S., Minoshima S., Shimizu N., Iwai K., Chiba T., Tanaka K., and Suzuki T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25 (2000) 302-305
39. Staropoli J.F., McDermott C., Martinat C., Schulman B., Demireva E., and Abeliovich A. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 37 (2003) 735-749
40. Tanaka M., Kim Y.M., Lee G., Junn E., Iwatsubo T., and Mouradian M.M. Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J. Biol. Chem. 279 (2004) 4625-4631
41. Ungerstedt U., and Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 24 (1970) 485-493
42. Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M., Harvey K., Gispert S., Ali Z., Del Turco D., Bentivoglio A.R., Healy D.G., Albanese A., Nussbaum R., Gonzalez-Maldonado R., Deller T., Salvi S., Cortelli P., Gilks W.P., Latchman D.S., Harvey R.J., Dallapiccola B., Auburger G., and Wood N.W. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 (2004) 1158-1160
43. Vercammen L., Van der Perren A., Vaudano E., Gijsbers R., Debyser Z., Van den Haute C., and Baekelandt V. Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease. Molec. Ther. 14 (2006) 716-723
44. West M.J., Slomianka L., and Gundersen H.J. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat. Rec. 231 (1991) 482-497
45. Wu P., Xiao W., Conlon T., Hughes J., Agbandje-McKenna M., Ferkol T., Flotte T., and Muzyczka N. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74 (2000) 8635-8647
46. Yamada M., Mizuno Y., and Mochizuki H. Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease. Hum. Gene Ther. 16 (2005) 262-270
47. Yang Y., Nishimura I., Imai Y., Takahashi R., and Lu B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 37 (2003) 911-924
48. Zetterstrom T., Herrera-Marschitz M., and Ungerstedt U. Simultaneous measurement of dopamine release and rotational behaviour in 6-hydroxydopamine denervated rats using intracerebral dialysis. Brain Res. 376 (1986) 1-7
49. Zhang K., and Kaufman R.J. The unfolded protein response: a stress signaling pathway critical for health and disease. Neurology 66 (2006) S102-S109
50. Zolotukhin S., Byrne B.J., Mason E., Zolotukhin I., Potter M., Chesnut K., Summerford C., Samulski R.J., and Muzyczka N. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6 (1999) 973-985
51. Zolotukhin S., Potter M., Zolotukhin I., Sakai Y., Loiler S., Fraites Jr. T.J., Chiodo V.A., Phillipsberg T., Muzyczka N., Hauswirth W.W., Flotte T.R., Byrne B.J., and Snyder R.O. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28 (2002) 158-167